Nadine Dohollou

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 157 citations

Medicine, Metronomic Therapy, Gynecology +8

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients.

Karim Fizazi, Nadine Dohollou, Jean‐Yves Blay et al. · Journal of Clinical Oncology · 1998 · 120 citations

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 111 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7